drugset / Trial / NCT03192332

Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke

NCT03192332

RandomizedParallel-groupSingle-blindTreatment

Summary

Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years. Whether IV t-PA prior to endovascular clot retrieval is beneficial for AIS patients with a proximal vessel occlusion in the anterior circulation has currently become a matter of debate and is a relevant unanswered question in clinical practice. The main objective is to determine whether subjects experiencing an AIS due to large intracranial vessel occlusion in the anterior circulation will have non-inferior functional outcome at 90 days when treated with direct mechanical thrombectomy (MT) compared to subjects treated with combined IV t-PA and MT. The secondary objectives are to study causes of mortality, dependency and quality of life in these AIS patients.

Timeline

Start
2017-11-29
Primary completion
2021-05-14
Completion
2021-08-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications